Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials

Taro Kishi, Yuki Matsuda, Nakao Iwata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We performed a meta-analysis to determine whether combination therapy with serotonin reuptake inhibitors (SRIs) and memantine (MEM) was beneficial for the treatment of obsessive- compulsive disorder. This study included three double-blind, randomized, placebo-controlled trials. MEM+SRI was superior to placebo+SRI with regard to response rate [primary outcome, n = 97; risk ratio = 0.22; 95% confidence intervals (CI) = 0.12-0.42; p < 0.00001; I 2 = 0%; number needed to treat = 2], the Yale- Brown Obsessive- Compulsive Scale total [standardized mean difference (SMD) = - 4.56; 95% CI = - 8.50, - 0.62; p = 0.02], obsession subscale (SMD = - 4.39; 95% CI = - 5.94, - 2.85; p < 0.00001), and compulsion subscale score (SMD = - 4.60; 95% CI = - 7.64, - 1.55; p = 0.003). No significant differences in any safety outcome were found between the groups.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalJournal of Alzheimer's Disease
Volume64
Issue number1
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Memantine
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Meta-Analysis
Randomized Controlled Trials
Placebos
Confidence Intervals
Obsessive Behavior
Numbers Needed To Treat
Therapeutics
Odds Ratio
Safety

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{f3bcf784c60b41e6a325e2cb4728908d,
title = "Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials",
abstract = "We performed a meta-analysis to determine whether combination therapy with serotonin reuptake inhibitors (SRIs) and memantine (MEM) was beneficial for the treatment of obsessive- compulsive disorder. This study included three double-blind, randomized, placebo-controlled trials. MEM+SRI was superior to placebo+SRI with regard to response rate [primary outcome, n = 97; risk ratio = 0.22; 95{\%} confidence intervals (CI) = 0.12-0.42; p < 0.00001; I 2 = 0{\%}; number needed to treat = 2], the Yale- Brown Obsessive- Compulsive Scale total [standardized mean difference (SMD) = - 4.56; 95{\%} CI = - 8.50, - 0.62; p = 0.02], obsession subscale (SMD = - 4.39; 95{\%} CI = - 5.94, - 2.85; p < 0.00001), and compulsion subscale score (SMD = - 4.60; 95{\%} CI = - 7.64, - 1.55; p = 0.003). No significant differences in any safety outcome were found between the groups.",
author = "Taro Kishi and Yuki Matsuda and Nakao Iwata",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-180237",
language = "English",
volume = "64",
pages = "43--48",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder

T2 - A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials

AU - Kishi, Taro

AU - Matsuda, Yuki

AU - Iwata, Nakao

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We performed a meta-analysis to determine whether combination therapy with serotonin reuptake inhibitors (SRIs) and memantine (MEM) was beneficial for the treatment of obsessive- compulsive disorder. This study included three double-blind, randomized, placebo-controlled trials. MEM+SRI was superior to placebo+SRI with regard to response rate [primary outcome, n = 97; risk ratio = 0.22; 95% confidence intervals (CI) = 0.12-0.42; p < 0.00001; I 2 = 0%; number needed to treat = 2], the Yale- Brown Obsessive- Compulsive Scale total [standardized mean difference (SMD) = - 4.56; 95% CI = - 8.50, - 0.62; p = 0.02], obsession subscale (SMD = - 4.39; 95% CI = - 5.94, - 2.85; p < 0.00001), and compulsion subscale score (SMD = - 4.60; 95% CI = - 7.64, - 1.55; p = 0.003). No significant differences in any safety outcome were found between the groups.

AB - We performed a meta-analysis to determine whether combination therapy with serotonin reuptake inhibitors (SRIs) and memantine (MEM) was beneficial for the treatment of obsessive- compulsive disorder. This study included three double-blind, randomized, placebo-controlled trials. MEM+SRI was superior to placebo+SRI with regard to response rate [primary outcome, n = 97; risk ratio = 0.22; 95% confidence intervals (CI) = 0.12-0.42; p < 0.00001; I 2 = 0%; number needed to treat = 2], the Yale- Brown Obsessive- Compulsive Scale total [standardized mean difference (SMD) = - 4.56; 95% CI = - 8.50, - 0.62; p = 0.02], obsession subscale (SMD = - 4.39; 95% CI = - 5.94, - 2.85; p < 0.00001), and compulsion subscale score (SMD = - 4.60; 95% CI = - 7.64, - 1.55; p = 0.003). No significant differences in any safety outcome were found between the groups.

UR - http://www.scopus.com/inward/record.url?scp=85048580200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048580200&partnerID=8YFLogxK

U2 - 10.3233/JAD-180237

DO - 10.3233/JAD-180237

M3 - Article

C2 - 29865079

AN - SCOPUS:85048580200

VL - 64

SP - 43

EP - 48

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -